Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 15/20 | 0.60 |
| ▸ | NPY1R | P25929 | 9/20 | 0.60 |
| ▸ | NPY5R | Q15761 | 8/20 | 0.60 |
| ▸ | NPY2R | P49146 | 5/20 | 0.60 |
| ▸ | CTSL | P07711 | 1/20 | 0.57 |
| ▸ | APC | P25054 | 3/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1663303 | 0.96 | APC (0.61) | NPY4RNPY1RNPY5RNPY2RCTSL | |
| SCHEMBL1660343 | 0.94 | CTSL (0.64) | NPY4RNPY1RNPY5RNPY2RCTSL | |
| SCHEMBL1661018 | 0.94 | CTSL (0.64) | NPY4RNPY1RNPY5RNPY2RCTSL | |
| SCHEMBL1661000 | 0.90 | NPY4R (0.60) | NPY4RNPY1RNPY5RNPY2RCTSL | |
| SCHEMBL29958868 | 0.90 | NPY4R (0.68) | NPY4RNPY1RNPY5RNPY2RAPC | |
| SCHEMBL10792006 | 0.89 | CTSL (0.54) | CTSL | |
| SCHEMBL8595159 | 0.89 | CTSL (0.54) | CTSL | |
| SCHEMBL5929274 | 0.88 | CTSL (0.73) | NPY4RNPY1RNPY5RNPY2RCTSL | |
| SCHEMBL30932537 | 0.87 | NPY4R (0.62) | NPY4RNPY1RNPY5RNPY2RAPC | |
| SCHEMBL29958885 | 0.87 | NPY4R (0.64) | NPY4RNPY1RNPY5RNPY2RAPC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3178836-A1 | GADD45BETA TARGETING AGENTS | Imperial Innovations Limited (GB) | 2017-06-14 | — | — | EP | claimed |
| US-20120277164-A1 | GADD45BETA TARGETING AGENTS | IMPERIAL INNOVATIONS LIMITED (GB) | 2012-11-01 | — | — | US | claimed |
| EP-2491051-A2 | GADD45BETA TARGETING AGENTS | Imperial Innovations Limited (GB) | 2012-08-29 | — | — | EP | claimed |
| WO-2011048390-A2 | GADD45BETA TARGETING AGENTS | IMPERIAL INNOVATIONS LIMITED (GB) | 2011-04-28 | — | — | WO | claimed |
| US-10697019-B2 | Method of diagnosis and prognosis | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2020-06-30 | — | — | US | disclosed |
| US-20170240592-A1 | GADD45BETA/MKK7 INHIBITOR FOR THE TREATMENT OF A RESISTANT HAEMATOLOGICAL MALIGNANCY | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2017-08-24 | — | — | US | disclosed |
| EP-3180350-A1 | GADD45BETA/MKK7 INHIBITOR FOR THE TREATMENT OF A RESISTANT HAEMATOLOGICAL MALIGNANCY | Imperial Innovations Ltd (GB) | 2017-06-21 | — | — | EP | disclosed |
| EP-3178836-A1 | GADD45BETA TARGETING AGENTS | Imperial Innovations Limited (GB) | 2017-06-14 | — | — | EP | disclosed |
| US-9518083-B2 | Gadd45beta targeting agents | IMPERIAL INNOVATIONS LIMITED (GB) | 2016-12-13 | — | — | US | disclosed |
| WO-2016024131-A1 | GADD45BETA/MKK7 INHIBITOR FOR THE TREATMENT OF A RESISTANT HAEMATOLOGICAL MALIGNANCY | IMPERIAL INNOVATIONS LIMITED (GB) | 2016-02-18 | — | — | WO | disclosed |
| US-20150368294-A1 | GADD45BETA TARGETING AGENTS | IP2IPO INNOVATIONS LIMITED (GB) | 2015-12-24 | — | — | US | disclosed |
| US-8993717-B2 | Gadd45beta targeting agents | IMPERIAL INNOVATIONS LIMITED (GB) | 2015-03-31 | — | — | US | disclosed |
| US-20140128330-A1 | METHOD OF DIAGNOSIS AND PROGNOSIS | IMPERIAL INNOVATIONS LIMITED (GB) | 2014-05-08 | — | — | US | disclosed |
| US-20120277164-A1 | GADD45BETA TARGETING AGENTS | IMPERIAL INNOVATIONS LIMITED (GB) | 2012-11-01 | — | — | US | disclosed |
| EP-2491051-A2 | GADD45BETA TARGETING AGENTS | Imperial Innovations Limited (GB) | 2012-08-29 | — | — | EP | disclosed |
| WO-2011048390-A2 | GADD45BETA TARGETING AGENTS | IMPERIAL INNOVATIONS LIMITED (GB) | 2011-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170240592-A1 | GADD45BETA/MKK7 INHIBITOR FOR THE TREATMENT OF A RESISTANT HAEMATOLOGICAL MALIGNANCY | MCL1, DDIT3, MAP2K7 | NPY4R 4859/4885NPY1R 4857/4885NPY5R 4808/4885 |
| US-20150368294-A1 | GADD45BETA TARGETING AGENTS | DDB1, CCL2, DDIT3 | NPY4R 2105/4885NPY1R 3277/4885NPY5R 2756/4885 |
| US-20120277164-A1 | GADD45BETA TARGETING AGENTS | DDB1, CCL2, DDIT3 | NPY4R 2105/4885NPY1R 3277/4885NPY5R 2756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.